Hogarty 1973 a.

Methods	Allocation: randomly assigned, stratified by sex, factorial design (2*2). Blinding : double, identical capsules. Duration: 3 years (preceded by 2 months stabilisation on chlorpromazine).
Participants	Diagnosis: schizophrenia (DSM II). N=374. Age: range 18‐53, mean 34 yrs. Sex: male and female. History: recently discharged, hospital<2 yrs, IQ>70. Excluded: serious suicidal or homicidal behaviour, organic brain syndrome, unmanageable drinking or drug abuse. Setting: community.
Interventions	1. Chlorpromazine cessation: placebo. N=182. 2. Chlorpromazine continuation: dose ˜270 mg/day. N=192. Factored to: A. Major Role Therapy. N=190. B. Rehabilitation counselling. N=184.
Outcomes	Relapse. Leaving study early. Unable to use ‐ Death: not reported by group. Trouble with police. not reported by group. Mental state: BPRS, symptom checklist, IMPS, SSI (no SD). Social functioning: Major Role Adjustment Inventory, Katz Adjustment Scale, Casework Evaluation Schedule. (no SD). Carer morbidity: Family Distress Scale. (no SD). Global state: KAS (no SD).
Notes
Risk of bias
Bias	Authors' judgement	Support for judgement
Allocation concealment (selection bias)	Unclear risk	B ‐ Unclear